Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Scholar Rock Holding Corp (SRRK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 485,314
  • Shares Outstanding, K 26,219
  • Annual Sales, $ 0 K
  • Annual Income, $ -25,000 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.56

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.51
  • Number of Estimates 3
  • High Estimate -0.35
  • Low Estimate -0.61
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.00 +23.40%
on 03/08/19
22.04 -16.02%
on 03/19/19
-0.06 (-0.32%)
since 02/22/19
3-Month
14.00 +32.21%
on 01/24/19
24.32 -23.89%
on 12/27/18
-0.69 (-3.59%)
since 12/21/18

Most Recent Stories

More News
Scholar Rock Reports Full Year 2018 Financial Results and Highlights Business Progress

-- Initiated and Progressed Phase 1 Clinical Trial of SRK-015 in Healthy Volunteers, Transitioning to a Clinical-Stage Company

SRRK : 18.51 (-3.99%)
Scholar Rock to Develop Cancer Immunotherapy Product Candidate, SRK-181, a Selective Inhibitor of TGFB1 Activation, to Overcome Checkpoint Inhibitor Resistance

Selective inhibition of TGFB1 activation enables immune cell entry into the tumor microenvironment in preclinical models, demonstrating potential for overcoming a key mechanism of primary resistance to...

SRRK : 18.51 (-3.99%)
Scholar Rock to Participate in Upcoming Investor Conferences

Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced...

SRRK : 18.51 (-3.99%)
Scholar Rock Announces Positive Interim Results from Phase 1 Trial of SRK-015 in Healthy Volunteers and Updates on Future Development Plans

-- Favorable Safety Profile Across All Tested Doses Supports Initiation of a Phase 2 Trial in Patients with Spinal Muscular Atrophy (SMA)

SRRK : 18.51 (-3.99%)
Sarepta's NDA for DMD Drug Golodirsen Gets Priority Review

FDA accepts Sarepta's (SRPT) regulatory application seeking approval for DMD therapy, golodirsen, and grants priority review. A decision is expected in August 2019.

SLDB : 10.24 (-2.94%)
SRPT : 122.26 (-3.47%)
PFE : 41.85 (-1.18%)
SRRK : 18.51 (-3.99%)
Biotech Stock Roundup: ALXN, ACOR Drugs' Get FDA Nod, AGEN up on GILD Deal

It was a busy week for the biotech sector with quite a few FDA approvals and some strategic partnerships.

AGEN : 2.82 (-5.37%)
STML : 12.37 (-6.71%)
GILD : 63.77 (-1.77%)
ACOR : 13.13 (-6.55%)
SRRK : 18.51 (-3.99%)
Gilead Partners with Scholar Rock for Fibrotic Disease Drugs

Gilead Sciences (GILD) collaborates with Scholar Rock Holding Corporation for the development of fibrotic disease candidates.

SGMO : 8.89 (-9.29%)
ABBV : 79.76 (-1.82%)
GILD : 63.77 (-1.77%)
SRRK : 18.51 (-3.99%)
Scholar Rock to Present at the BMO 2018 Prescriptions for Success Healthcare Conference

Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced...

SRRK : 18.51 (-3.99%)
Scholar Rock Announces Publication of Preclinical Data on the Therapeutic Benefit of Inhibiting Myostatin Activation in Models of Spinal Muscular Atrophy

Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced...

SRRK : 18.51 (-3.99%)
Scholar Rock Announces the Addition of Edward (Ted) Myles to Its Board of Directors

Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced...

SRRK : 18.51 (-3.99%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade SRRK with:

Business Summary

Scholar Rock Holding Corporation is a biopharmaceutical company. It focused on the discovery and development of medicines for treatment of serious diseases. The company's product candidate includes SRK-015 and BMP6 which is in pre-clinical stage. Scholar Rock Holding Corporation is based in Cambridge,...

See More

Key Turning Points

2nd Resistance Point 19.56
1st Resistance Point 19.03
Last Price 18.51
1st Support Level 18.15
2nd Support Level 17.79

See More

52-Week High 30.00
Fibonacci 61.8% 23.54
Fibonacci 50% 21.55
Fibonacci 38.2% 19.55
Last Price 18.51
52-Week Low 13.09

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar